Application of Immune Checkpoint Inhibitors in EGFR Mutant
Advanced Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2022.102.32
- Author:
Yujun ZHENG
1
;
Wei JIANG
1
;
Jing LI
1
;
Lulu DAI
1
;
Dongyan CHEN
1
;
Yanjun LI
1
;
Lei HUANG
1
;
Mingji WANG
1
Author Information
1. The Friendship Hospital of Dalian, Dalian 116001, China.
- Publication Type:Journal Article
- Keywords:
Inmune checkpoint inhibitors;
Lung neoplasms;
Molecular characteristics
- MeSH:
B7-H1 Antigen/metabolism*;
Carcinoma, Non-Small-Cell Lung/pathology*;
ErbB Receptors/metabolism*;
Humans;
Immune Checkpoint Inhibitors/therapeutic use*;
Ligands;
Lung Neoplasms/pathology*;
Mutation;
Tumor Microenvironment
- From:
Chinese Journal of Lung Cancer
2022;25(9):671-677
- CountryChina
- Language:Chinese
-
Abstract:
In recent years, immune checkpoint inhibitors (ICIs) have greatly improved the survival rate of non-small cell lung cancer (NSCLC) patients without driver mutation. Compared with wild-type tumors, tumors with epidermal growth factor receptor (EGFR) mutations have greater heterogeneity in immune microenvironment characteristics such as programmed cell death ligand 1 (PD-L1) and tumor mutational burden (TMB). Whether ICIs is suitable for NSCLC patients with EGFR mutation has been controversial. Clinical studies have shown that immunomonotherapy has no significant effect on patients with EGFR mutant NSCLC. ICIs combined with chemotherapy and antiangiogenic drugs show good survival benefits. This paper overviews the clinical research and related mechanism of ICIs single drug or combination therapy inadvanced NSCLC patients with EGFR mutation.
.
